Continuing Medical Education Program - Purchase Activities
The purpose of The Medical Letter Continuing Medical Education Program is to provide a means for healthcare professionals (including physicians, physician assistants, nurse practitioners, and pharmacists) to keep up to date with new drugs and changes in therapeutics. The objectives of the program are to educate the participants, impact clinical practice, and improve patient outcomes. The Medical Letter CME Program is funded by fees paid by the activity participants. The Medical Letter is free of commercial influence and financial sponsorship.

  The Medical Letter Individual Activities — Online Only
I would like to order the following Per Issue Activities eligible for 2 credits each: $15
per activity
1556  (2 credits)   Expires 09/24/2019
Antiviral Drugs for Varicella-Zoster Virus and Herpes Simplex Virus Infections
Hydrogen Peroxide 40% (Eskata) for Seborrheic Keratoses
Elagolix (Orilissa) - An Oral GnRH Antagonist for Endometriosis Pain
1557  (2 credits)   Expires 10/08/2019
Choice of Contraceptives
1558  (2 credits)
Influenza Vaccine for 2018-2019
Tezacaftor/Ivacaftor (Symdeko) for Cystic Fibrosis
OTC Brimonidine (Lumify) for Ocular Redness
1559  (2 credits)
Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
Plazomicin (Zemdri) - A New Aminoglycoside Antibiotic
Cannabidiol (Epidiolex) for Epilepsy
1560  (2 credits)
Vaccines for Travelers
1561  (2 credits)
Baloxavir Marboxil (Xofluza) for Treatment of Influenza
Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events
Sodium Zirconium Cyclosilicate (Lokelma) for Hyperkalemia
Angiotensin II (Giapreza) for Septic Shock
1562  (2 credits)
Drugs for Chronic Insomnia
Drugs for Cough
1563  (2 credits)
Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza
Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis
Dupilumab (Dupixent) for Asthma
1564  (2 credits)
OTC Primatene Mist Returns
Qbrexza - A Glycopyrronium Cloth for Axillary Hyperhidrosis
Plenvu - A Low-Volume PEG-Based Colonoscopy Preparation
Revefenacin (Yupelri) for COPD
Aripiprazole with Digital Ingestion Tracking (Abilify MyCite)
1565  (2 credits)
Lipid-Lowering Drugs
1566  (2 credits)
An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
Fostamatinib (Tavalisse) for ITP
Oxybutynin for Hot Flashes in Women with Breast Cancer
Drug Interaction: Opioids and Oral P2Y12 Platelet Inhibitors
1567  (2 credits)
Drugs for Gout
Xyosted - A Testosterone Auto-Injector for Hypogonadism
Rifamycin (Aemcolo) for Treatment of Travelers' Diarrhea
1568  (2 credits)
ZTlido - A New Lidocaine Patch for Postherpetic Neuralgia
Sarecycline (Seysara) - Another Oral Tetracycline for Acne
Sulfonamide Cross-Reactivity
Desmopressin (Nocdurna and Noctiva) for Nocturnal Polyuria
1569  (2 credits)
Drugs for Chronic Heart Failure
Esketamine Nasal Spray (Spravato) for Treatment-Resistant Depression
1570  (2 credits)
OTC Drugs for Seasonal Allergies
Eravacycline (Xerava) - An IV Tetracycline for Complicated Intra-Abdominal Infections
Ozenoxacin 1% Cream (Xepi) for Impetigo
1571  (2 credits)
Insulins for Type 2 Diabetes
Brexanolone (Zulresso) for Postpartum Depression
Siponimod (Mayzent) - A New Drug for Multiple Sclerosis
Tegaserod (Zelnorm) Returns
1572  (2 credits)
Inhaled Levodopa (Inbrija) for Parkinson's Disease
Omadacycline (Nuzyra) - A New Tetracycline Antibiotic
Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A
PrabotulinumtoxinA (Jeuveau) for Frown Lines
1573  (2 credits)
Risankizumab (Skyrizi) for Psoriasis
Romosozumab (Evenity) for Postmenopausal Osteoporosis
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
1574  (2 credits)
Drugs for Psoriasis
1575  (2 credits)
Colorectal Cancer Screening
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
Tafenoquine (Arakoda and Krintafel) for Malaria
1576  (2 credits)
Drugs for Smoking Cessation
Benzhydrocodone/Acetaminophen (Apadaz) for Pain
1577  (2 credits)
Zolgensma - One-Time Gene Therapy for Spinal Muscular Atrophy
Bremelanotide (Vyleesi) for Hypoactive Sexual Desire Disorder
Cyclosporine 0.09% Solution (Cequa) for Dry Eye Disease
Cladribine (Mavenclad) for Multiple Sclerosis
1578  (2 credits)
Drugs for Anxiety Disorders
Jornay PM - Evening-Dosed Methylphenidate for ADHD
1579  (2 credits)
Insect Repellents
Solriamfetol (Sunosi) for Excessive Daytime Sleepiness
Dolutegravir/Lamivudine (Dovato) - A Two-Drug Complete Regimen for HIV-1 Infection
Risk of Pulmonary Thromboembolism and Death with Tofacitinib (Xeljanz)
1580  (2 credits)
Drugs for Atrial Fibrillation


ACCME The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Letter Inc. designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This Continuing Medical Education (CME) activity was planned and produced in accordance with the ACCME Essentials and Policies.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Your participation information will be shared with ABIM through PARS.

AAFP This Enduring Material activity, The Medical Letter Continuing Medical Education Program, has been reviewed and is acceptable for credit by the American Academy of Family Physicians. Term of approval begins 01/01/2019. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA This program has been reviewed and is approved for a maximum of 52.00 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of 01/01/2019. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs. Successful completion of the post-test is required to earn AAPA Category 1 CME credit. Successful completion is defined as a cumulative score of at least 70 percent correct.

Accreditation Council on Pharmacy Education
The Medical Letter is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Each exam is acceptable for 2.0 hour(s) of knowledge-based continuing education credit (0.2 CEU).